Los Angeles Capital Management & Equity Research Inc. Buys 100 Shares of Pharmerica Corporation (PMC)
Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Pharmerica Corporation (NYSE:PMC) by 0.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,614 shares of the company’s stock after buying an additional 100 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Pharmerica Corporation were worth $305,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of PMC. SG Americas Securities LLC bought a new position in Pharmerica Corporation during the 1st quarter worth $121,000. Russell Investments Group Ltd. grew its stake in Pharmerica Corporation by 124.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,886 shares of the company’s stock worth $128,000 after buying an additional 2,710 shares during the last quarter. State of Alaska Department of Revenue grew its stake in Pharmerica Corporation by 79.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,112 shares of the company’s stock worth $160,000 after buying an additional 2,712 shares during the last quarter. US Bancorp DE grew its stake in Pharmerica Corporation by 41.3% during the 1st quarter. US Bancorp DE now owns 7,121 shares of the company’s stock worth $167,000 after buying an additional 2,081 shares during the last quarter. Finally, Mason Street Advisors LLC grew its stake in Pharmerica Corporation by 7.0% during the 1st quarter. Mason Street Advisors LLC now owns 7,200 shares of the company’s stock worth $168,000 after buying an additional 474 shares during the last quarter. Hedge funds and other institutional investors own 92.15% of the company’s stock.
Pharmerica Corporation (NYSE:PMC) opened at 29.15 on Thursday. Pharmerica Corporation has a 12 month low of $19.20 and a 12 month high of $29.40. The firm’s 50-day moving average price is $28.94 and its 200-day moving average price is $25.67. The firm has a market cap of $907.18 million, a price-to-earnings ratio of 39.50 and a beta of 0.84.
Pharmerica Corporation (NYSE:PMC) last released its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.47. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The firm had revenue of $592.00 million during the quarter, compared to analysts’ expectations of $592.96 million. During the same period last year, the firm posted $0.47 EPS. The business’s revenue was up 13.9% on a year-over-year basis. Equities research analysts predict that Pharmerica Corporation will post $1.94 earnings per share for the current year.
A number of research analysts recently commented on the company. Barrington Research downgraded Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. KeyCorp downgraded Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday. ValuEngine downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Finally, UBS AG restated a “neutral” rating and set a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $30.50.
TRADEMARK VIOLATION NOTICE: “Los Angeles Capital Management & Equity Research Inc. Buys 100 Shares of Pharmerica Corporation (PMC)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/28/los-angeles-capital-management-equity-research-inc-buys-100-shares-of-pharmerica-corporation-pmc.html.
About Pharmerica Corporation
Receive News & Stock Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related stocks with our FREE daily email newsletter.